Biomarkers /
CCND1
Overview
Cyclin D1 (CCND1) is a gene that encodes a protein that functions in the regulation of CDK kinases in the cell cycle. Fusions, rearrangements, missense mutations, nonsense mutations, silent mutations, and in-frame deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
CCND1 is altered in 4.10% of all cancers with breast invasive ductal carcinoma, invasive breast carcinoma, bladder urothelial carcinoma, breast invasive lobular carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CCND1 are CCND1 Amplification (3.83%), CCND1 Mutation (0.62%), CCND1 Loss (0.04%), CCND1 P287S (0.05%), and CCND1 Fusion (0.05%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of CCND1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.